DAY 1
Wednesday, 27 May 2026
8h15
Welcome coffee and registration
8h45
Welcome address
- Plenary
Chairman
Yves Jacob
R&D Lead France
Sanofi - France
Oumeya Adjali
President
French Society of Cell and Gene Therapy (SFTCG) - France
9h05
Regulatory T cells: From Nobel Prize to drug pipeline reality?
Gavin Vuddamalay
Head of Scientific Affairs & Business Intelligence
MabDesign - France
9h15
Keynote lecture
- Plenary
Chairman
9h15
Accelerating Gene Therapy with Organoids & Droplet Microfluidics: Customizable High Throughput Single-Cell RNA-seq for AAV Library Screening
Timea Marton
Co‑leader of Sanofi’s contribution to the Viral Vector
Intelligent Design for Gene Therapy (WIDGeT) consortium
Sanofi - France
9h45
Track 1: Next-Generation RNA Therapies
- Plenary
Chairman
9h45
What if RNA therapeutics could be delivered orally?
Henri Pierre
CEO and Co-Founder
Oragen Therapeutics - France
10h05
Delivery of the Cas9/sgRNA ribonucleoprotein complex in vitro and in vivo through virus-like particles (“Nanoblades”)
Emiliano Ricci
Researcher
ENS Lyon - France
10h25
Converting a Hematopoietic Mutation into a Therapeutic Cytotoxic Payload via mRNA-LNP Delivery
Chantal Lagresle
Researcher
Imagine Institute - France
10h45
Q&A Session
11h00
Coffee break - Exhibition Hall
11h30
Roundtable - China's Rise and What It Means for the Future of Biopharma
- Plenary
Animated by MabDesign
Gavin Vuddamalay
Head of Scientific Affairs & Business Intelligence
MabDesign - France
Caroline Man Xu
Co-founder and CEO
VeonGen Therapeutics - Germany
Sergio Lainez Vicente
Associate Director, Business Development
Pharmaron - Spain
Sophie Zhou Goulvestre
Strategy and Management Specialist for Franco-Chinese B2B Activities
SR2C Consulting & Management - France
Mathilde Salavin
Law Firm Partner
MCE Carrel - France
12h15
Lunch - Exhibition Hall - B2B Meetings
13h45
Keynote lecture
- Plenary
Chairman
13h45
Advancing In Vivo RNA Therapies Towards Clinical in B Cell Mediated Autoimmune Diseases
Gilles Besin
Head of RNA and in vivo CAR
Bristol-Myers Squibb - USA
14h15
Track 2: Exploring the Future of CARs (ex vivo & in vivo)
- Plenary
Chairman
14h15
From Vein-to-Vein to On-Demand: Redefining CAR Manufacturing
Carmen Sanges
Executive Board Member
T2EVOLVE - Germany
14h35
Metabolically Programmed Hyper-Targeting Pluripotent Stem Cell Derived Natural Killer Cells for Adoptive Cell Immunotherapy
Niels-Bjarne Woods
Associate Professor, Section Molecular Medicine and Gene Therapy
Lund University - Sweden
14h55
Allogeneic T Cell Precursors: Toward a True Off-the-Shelf T Cell Immunotherapy
Inna Menkova
CEO
Allogenica - France
15h15
Q&A Session
15h30
In Vivo CAR T Cell Generation Across Species Using Targeted Ionizable Lipid Nanoparticles
Emmanuelle Cameau
Scientific Director, Genomic Medicine
Cytiva - France
15h40
Short break
15h45
Workshops
Roundtable: Successful implementation of QC : Key considerations for the right support of your projects
by bioMérieux
Elsa Kress
Head of Business Development
MabDesign - France
Philippe Béchaud
Marketing Director,
Pharma QC France
bioMérieux - France
Marc Meichenin
Chief Scientific Officer
Clean Cells - France
Guillaume Sirgue
Director Technical Excellence
Oxford Biomedica - France
Christelle Rochon
Head of Strategic partnerships
and BD /CMC consultant
INITS - France
Hélène Nègre
Head of Market Analysis
and Development Department
CELLforCURE by Seqens - France
Workshop: Accelerating personalized CRISPR therapies
by Aldevron
Tim Traynor
Senior Technical Sales Specialist
Aldevron - USA
Abdelilah Mekhloufi
Field Application Scientist -
Gene Editing
IDT - France
Martin Rabel
Service Solution Specialist
Cytiva - Germany
16h30
Coffe Break - Exhibition Hall - B2B Meetings
17h00
Breakthrough innovation session
- Plenary
Chairman
17h00
Beyond Averages: Direct Mass Analysis of Viral Vectors Using CDMS
Ben Wilkes
Principal Biologics Market Development Manager
Waters - United Kingdom
17h10
Viro-ID -Enhancing Virus Analysis through Nanopore Technology
Léa Chazot-Franguiadakis
Research engineer
ENS - France
17h20
From Development to Clinical Batches: EFS Bioproduction and its PIBT Integrator Driving Innovation in High-Quality, Tailored Cell Therapy Manufacturing
Clémentine Gamonet
Head of Bioproduction Development and Scientific Director of the Biotherapy Innovation Hub
EFS – Etablissement Français du Sang - France
Hubert Mechain
Head of Global ATMP Bioproduction
EFS – Etablissement Français du Sang - France
17h30
LockSeq: Ensuring genomic safety in gene therapies through high-fidelity NGS validation
Felix Neumann
CEO
Countagen - Sweden
17h40
MitoStem is a small molecule solution for universal and robust stem cell-like memory CAR T cell induction
Augustin de Bettignies
Chief Business Officer & Chairman of the board
MPC Therapeutics - Switzerland
17h50
Protein engineering strategies to support cell and gene therapy reagent ecosystem
Martial Dufour
Regional Sales Manager France, Spain, Portugal & Middle East
Proteintech - France
18h00
Nuclease Choice as a Lever for Yield and Cost in Viral Vector Production
Lionel Malbec
Senior Product Manager
ArcticZymes Technologies - Norway
18h10
New modified poloxamers enhancing virus efficiency for cell therapy engineering
Sofia Muret
Sales & Marketing Manager
OZ Biosciences - France
18h20
Innovations Advancing the CGT Field: Practical Solutions to address key challenges in Cell therapy development and manufacturing
Idil Ariöz
Technical Sales Supervisor, West-South Europe
ACROBiosystems - Netherlands
18h30
Cocktail Reception hosted by Sanofi
21h30